Expand all sections

Rifaximin

Xifaxan

Extended indication Prikkelbaredarmsyndroom.
Therapeutic value No judgement
Total cost 999,600,000.00

Product

Active substance Rifaximin
Domain Chronic immune diseases
Main indication Bowel diseases
Extended indication Prikkelbaredarmsyndroom.
Proprietary name Xifaxan
Manufacturer Norgine
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Antibioticum dat al beschikbaar is in Nederland.

Registration

Registration route Centralised (EMA)
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Frequency of administration 2 times a day
Dosage per administration 550 mg

Expected patient volume per year

Patient volume

< 238,000

Market share is generally not included unless otherwise stated.
References NHG
Additional remarks De prevalentie is voor mannen 4 per 1000 en voor vrouwen 10 per 1000. (NHG). 17 mln*14/1000= 238.000 personen maximaal.

Expected cost per patient per year

Cost < 4,200.00
References Medicijnkosten.nl
Additional remarks €6,08 per pil van 550mg. € 4441,06 pppj

Potential total cost per year

Total cost

999,600,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.